-
- bluebird bio
to receive
“bb21217, bluebird’s second oncology program to enter the clinic,
complements bb2121, which has demonstrated encouraging safety and
efficacy results in an ongoing Phase 1 trial. With bb21217, we
manufacture a CAR T cell product enriched for ‘memory T cells’ – a
long-lived, more potent T cell subtype – which in preclinical in vivo
studies has shown improved anti-tumor activity,” said
“The advancement of bb21217 into the clinic builds upon the success of
our first-generation program and is one more testament to bluebird’s and
Celgene’s combined leadership in the field of anti-BCMA CAR T
therapies,” said
The bluebird bio and
About the CRB-402 Study
The primary objective of the CRB-402
study is to evaluate the maximum tolerated dose of bb21217 and determine
the recommended Phase 2 dose. The secondary objective is preliminary
efficacy data, measured using the
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio’s gene therapy clinical programs include its Lenti-D™ product
candidate, currently in a Phase 2/3 study, called the Starbeam Study,
for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin® BB305
product candidate, currently in three clinical studies for the treatment
of transfusion-dependent β-thalassemia, also known as β-thalassemia
major, and severe sickle cell disease. bluebird bio’s oncology pipeline
is built upon the company’s leadership in lentiviral gene delivery and T
cell engineering, with a focus on developing novel T cell-based
immunotherapies, including chimeric antigen receptor (CAR T) and T cell
receptor (TCR) therapies. bluebird bio’s lead oncology programs, bb2121
and bb21217, are anti-BCMA CAR T programs partnered with
bb2121 and bb21217 are investigational therapies that have not been not been approved by any regulatory agency and for which the safety and efficacy have not been established.
bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline.
bluebird bio has operations in
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the clinical and market potential of the Company’s anti-BCMA oncology
program, including the bb2121 and bb21217 product candidates. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risk that the preclinical efficacy and safety data for our
bb21217 product candidate will not be observed in the CRB-402 clinical
study, the risk of cessation or delay of any of the ongoing or planned
clinical studies and/or our development of our product candidates, the
risk of a delay in the enrollment of patients in our clinical studies,
the risk that our collaboration with
View source version on businesswire.com: http://www.businesswire.com/news/home/20170928006294/en/
Source: bluebird bio, Inc.
bluebird bio
Investors & Media
Elizabeth Pingpank,
617-914-8736
epingpank@bluebirdbio.com